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Abstract
Background: Neospora caninum is an important cause of infectious abortion and stillbirth in cattle
world-wide. Infection is common and may frequently be passed from mother to calf (vertical
transmission) with no signs of disease. Based on our previous observation that N. caninum-infection
can be efficiently controlled with Toltrazuril-sulfone (Ponazuril) in experimentally infected mice, we
addressed the question if efficacy could also be obtained in experimentally infected calves.
Material and Methods: The study included 19 calves and represents an initial explorative
approach to document a basic effectiveness at first. Fifteen animals received each 2 x 108N. caninum
trophozoites, half of the dose being injected intravenously and the other half subcutaneously.
Efficacy of treatment was assessed using molecular detection of parasite DNA with PCR and
pathological alterations by immunohistochemistry in different organs of the animals. Assessment
included also clinical, serological and pathophysiological parameters.
Results: In those calves medicated with ponazuril (one, or six consecutive days, respectively,
starting one day after infection), a complete abrogation of the parasite detectability was obtained
in the brain and other organs, while 50% of non-treated calves became PCR-positive in brain and
muscles. Clinically, ponazuril chemotherapy of infected calves – in comparison to non-treated
infected animals – reduced symptoms (fever), but no differences were observed between treated
and non-treated animals with regard to serum enzymes and metabolites. Efficacy of a six-day
treament was also reflected by significantly lower anti-Neospora antibody concentrations developed
after infection, when compared to non-treated animals.
Conclusion: Based on our findings in this initially explorative approach that indicate a basic
effectiveness of ponazuril against experimental N. caninum infection in calves, we plan to follow our
chemotherapeutical intervention strategy to control bovine neosporosis with a subsequent more
extensive field study with naturally infected calves.
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Infectious organisms can cause significant losses in farm
ruminant production as a result of abortion, embryonic
damage or maternal infertility. One of the principal agents
causing protozoal abortion or still-birth in cattle is Ne-
ospora caninum[1,2]. Infection affects approximately 12%
of Swiss cattle [3] and may frequently be passed from
mother to calf (vertical transmission) with no signs of dis-
ease. Problems occur when the parasite multiplies in the
developing calf or the affected placenta and causes suffi-
cient damage to trigger stillbirth or abortion, respectively.
Preliminary research suggests that infection of the foetus
early in gestation is more likely to be fatal to the conceptus
than infection later in gestation [4]. However it also ap-
pears that infection is more likely to be transmitted in late
rather than early pregnancy. Thus the majority of infec-
tions are not symptomatic and inapparent infections are
maintained and linearly expanded in a herd. Control of
bovine neosporosis is difficult. Effective vaccines to pro-
tect cattle from abortion or vertical parasite transmission
are currently not available [1,5]. Pharmacologically active
compounds are known to kill N. caninum[6]. Thus, toltra-
zuril and ponazuril proved high efficacy to prevent para-
site dissemination and subsequent cerebral lesion
formation in a murine experimental model [7]. To assess
treatment efficacy, mice were clinically investigated for
symptoms; histologically by searching respective cerebral
lesions and molecular biologically by detection of parasite
DNA using the polymerase-chain-reaction (PCR). Efficacy
of treatment was demonstrated to eliminate the parasite,
and to reduce but not to abrogate parasite-specific humor-
al immunity in mice.
With regard to controlling infection, disease or diaplacen-
tal parasite transmission in cattle, a chemotherapeutical
approach has not been studied yet. Therefore, we de-
signed now an initial explorative approach to document a
basic effectiveness at first. This experiment represents a
simple first step, to be followed with a more extensive, but
also more expensive future study to provide a statistically
evidence of the effect in large numbers of animals. To
monitor treatment efficacy in the experimentally infected
calves of this study, we used the same parameters as out-
lined above in the mouse model.
Materials and Methods
Parasites
Host Vero cells were maintained in 75 cm2 tissue culture
flasks in 20 ml RPMI 1640 medium supplemented with
25 mM HEPES, 2 mM L-glutamine, 50 IU/ml penicillin,
50 g/ml streptomycin and 10% fetal calf serum (FCS)
(Gibco BRL, Life Technologies), and cultivation was as
previously described [8]. Neospora caninum (NC-1 isolate)
was cultivated in 75 or 175 cm2 culture flasks on Vero cells
using the same medium but replacing FCS with 10% gam-
ma-globulin-free horse serum (Gibco BRL, Life Technolo-
gies). Isolation and purification of in vitro-generated
parasites were done as previously described [8]. Briefly,
Vero cells infected with N. caninum were passaged through
a 25G 5/8 needle, washed and run on PD-10 Sephadex G-
25 M columns. Eluted tachyzoites were counted in a Neu-
bauer-chamber and tested for viability by trypan blue ex-
clusion. Tachyzoites were either directly used for infection
of calves or stored frozen at -80C for subsequent antigen
processing. Crude somatic antigens from frozen N. cani-
num (SA-antigen) for the enzyme-linked immunosorbent
assay (ELISA) was produced as described earlier [9].
Calves
The study included 19 male calves with a mean body
weight of 85 kg (range 60 – 108 kg) and a mean age of 70
days (range 42 to 98 days old) at the day of infection. All
animals tested were serologically negative (N. caninum-In-
direct-Fluorescence-Antibody-Tests (IFAT) and N. cani-
num-ELISA, according to [10]) prior to infection. The
calves had free access to hay and water ad libitum. Further-
more, they had access to a drinking-automate (UFA AG,
Sursee, Switzerland) that provided to each calf a body
weight-dependent quantity of fresh milk obtained daily
from N. caninum seronegative lactating cows. One-hun-
dred liter fresh milk was complemented with 55 grams of
a pre-mix (UFA top-fit PreVitin, Sursee, Switzerland).
Calves were sacrificed by deactivation of the Medulla ob-
longata and subsequent bleeding. Organs were carefully
removed and subsequently dissected by the use of dispos-
able tools in order to avoid any cross-contamination. All
calves were housed and handled under standard animal
experimentation conditions respecting the rules of the
Swiss regulation of animal experimentation; the experi-
ments were accepted and validated by the governmental
regulation committee and obtained the permission no. 7/
01.
Experimental infection
Each calf received 2 x 108N. caninum trophozoites for in-
fection. The dose was divided into 1 x 108N. caninum tro-
phozoites suspended in 5 ml sterile phosphate-buffered-
saline (PBS) to be injected intravenously (i.v.) and an
identical dose injected subcutaneously (s.c.). Non-infect-
ed control animals received an appropriate number of
Vero-cells i.v. and s.c.. In order to monitor the infectivity
status of the tachyzoites used for experimental infection of
calves, 2 mice were additionally infected with 2 x 106 par-
asites i.p.. These mice were sacrificed 29 days post infec-
tionem (p.i.) and investigated for the presence of N.
caninum as previously reported [9].
Study design and experimental ponazuril therapy
With regard to infection and treatment schedules, the
calves were assigned into the following groups:Page 2 of 10
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trols
Group 2 (2 calves): non-infected controls with medica-
tion (medication: 6 consecutive days of chemotherapy
starting at 1 day post infectionem, d.p.i.)
Group 3 (6 calves): infected and non-medicated (positive)
controls
Group 4 (5 calves): infected and medicated (medication:
1 day of chemotherapy starting at 1 d.p.i.)
Group 5 (4 calves): infected and medicated (medication:
6 consecutive days of chemotherapy starting at 1 d.p.i.)
Medication was performed perorally with 20 mg ponaz-
uril (toltrazuril-sulfone) per kg body weight, using a 5%
ponazuril suspension. The first medication dose was ap-
plied 24 h after infection, and, if repeated, every subse-
quent 24 hours for six days.
Per group, half of the calves were sacrificed on day 45 and
the other on day 90 p.i., respectively (for group 5, three
animals on day 45 and two on day 90 p.i.).
N. caninum-specific PCR
N. caninum – specific PCR was performed with 10 samples
isolated from all sacrificed calves. Each brain sample was
independently homogenized with a stirrer and DNA was
isolated from 50 to 100 l homogenate using the
DNeasy™ kit (Qiagen, Basel, Switzerland) according to the
manufacturer's recommendations. Neospora-specific PCR
was done as described before [10–12]. For PCR analyses
and per animal, a total of 10 different samples were col-
lected from the brain (4 samples from the main cranial
lobe, 4 from the main caudal lobe, 2 from the cerebel-
lum), 3 from the heart and 3 from the muscles (one from
the masseter, one from the diaphragma and one from the
tongue), see Table 1. In addition, single probes were col-
lected from the GI-tract, the liver, the spleen, the lungs,
the pancreas and from popliteal lymphnodes. These
probes were only PCR-investigated for infected and non-
treated calves.
Histology and immunohistochemistry
Sections of formalin fixed and paraffin-embedded tissues
were haemalaun-eosin stained for microscopic examina-
tion or were used for immunohistochemistry as described
elsewhere [10]. Samples from the brain, heart, lung, liver
and kidney were examined.
Serology
Antibodies against N. caninum were detected by an en-
zyme-linked immunosorbent assay (ELISA) using a solu-
ble somatic antigen [10]. N. caninum-seropositivity was
primarily defined by an ELISA-value  1 antibody units
[12].
Clinical and pathophysiological parameters
Rectal temperature
The body temperature of calves was rectally assessed in the
morning between 08:00 h and 08:30 h, this in parallel to
the drawing of blood samples.
Gain of body weight
Body weight of each individual animal was assessed once
per week, starting 4 weeks before initiation of infection
and or medication, until the end of experiments.
Table 1: PCR-results with a total of 380 tissue samples obtained from non-infected (control) and N. caninum-infected calves without and 
with ponazuril therapy (1T = medication for one day; 6T = medication for 6 consecutive days). Bold numbers indicate the number of 
positive samples per total number of samples analyzed; – means that no sample was PCR-positive. Infected animals without therapy 
were euthanized on day 45 p.i. (nos. 1–3) and 90 p.i. (nos. 4–6)
without infection infection, without therapy infection, with therapy
() = number of 
calves tested
without therapy 
(2)
with 
therapy_6T 
(2)
no.1 
(1)
no.2 
(1)
no.3 
(1)
no.4 
(1)
no.5 
(1)
no.6 
(1)
with therapy_1T 
(5)
with 
therapy_6T 
(4)
brain - / 20 - / 20 - / 10 2 / 10 - / 10 - / 10 1 / 10 - / 10 - /50 - /40
heart - / 6 - / 6 - / 3 - / 3 1 / 3 - / 3 - / 3 - / 3 - /15 - /12
muscles* - / 6 - / 6 - / 3 1 / 3 - / 3 - / 3 1 / 3 - / 3 - /15 - /12
liver - / 8 - / 8 - / 4 - / 4 - / 4 - / 4 - / 4 - / 4 - /20 - /16
*muscles: per animal, one sample from the M. masseter, one from the diaphragma and one from the tongue, respectively.Page 3 of 10
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Plasma levels of glucose, urea, non-estered fatty acids
(NEFA) and triglycerides, enzymes [(aspartate-amino-
transferase (AST), gamma-glutamyle-transferase (-GT),
creatine-kinase (CK) and glutamate-dehydrogenase
(GLDH)] were assessed in blood samples taken at 0, 1, 2,
3 and 4 d.p.i, using appropriate test kits purchased from
Hoffmann-La-Roche (Basel, Schweiz) (kit nos. # 07 3685
6, # 07 3679 1, # 07 3671 6, # 07 3641 4, # 07 3655 4 and
# 07 3647 3), from Wako Chemicals (Neuss, Germany)
(kit no. # 994–75409) and from Boehringer (Ingelheim,
Germany) (kit no # 124311), respectively. Kit perform-
ance occurred in a Cobas Mira plus analyzer (Roche, Ba-
sel, Switzerland). Prior to testing, plasma samples were
stored at -20C.
Ponazuril serum levels
For each animal, several (see Fig. 3) serum samples were
stored frozen (-20C) for a subsequent determination of
the ponazuril serum level. Ponazuril was determined by
HPLC with fluorescence detection after post column deri-
vatisation with UV-light at the laboratory for Animal
Health, Bayer AG, Crop Protection Development,
Leverkusen, together with pharmacokinetic calculations,
both according to the method previously described in Furr
and Kennedy [13]. Half life times were calculated by anal-
ysis with the software package TOPFIT 2.0 using the non
compartment model.
Statistical analyses
Due to only explorative status of this first study, and the
thus minimal number of calves used for each experimen-
Figure 1
Anti-Neospora caninum serum IgG measured by ELISA in non-infected and non-medicated negative control calves (c), infected
and non-medicated positive control calves (I_w/oT), infected and one-day medicated calves (I_1T) and infected and six-day
medicated calves (I_6T). Number of animals per group as in Table 1. AU = antibody units; dotted line (cut-off) indicates the
negative/positive threshold determined by the mean plus 3 S.D. of measurements from non-infected control calves. Error bars
display standard deviations.
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tensity and extensity data. The study classifies therefore as
a preliminary descriptive experiments, results expressing
tendencies. However, for serological data analysis, the
software package Revelation® from Microtech (Embrach,
Switzerland) could be used for statistics.
Results
Infection and effect of treatment
The infection intensity and extensity was analyzed by PCR
specific for N. caninum DNA (Table 1) and by immuno-
histochemistry, including brain, heart and muscle sam-
ples from all 19 calves of the experiment. In non-
medicated control-infected calves, the presence of N. cani-
num-DNA was confirmed by PCR in three out of six calves,
affecting the brain and muscles in two, and the heart only
in another animal. All 11 infected and ponazuril-treated
calves remained negative in PCR for all samples tested. As
all samples derived from the GI-tract, the liver, the spleen,
the lungs, the pancreas and lymphnodes were PCR-nega-
tive in infected and non-treated animal, thus we did not
perform the respective PCR with the other calves used in
the experiment. In the histological analyses of the calf
brains, no multifocal cerebral micro-lesions could be de-
tected, neither in PCR-negative nor in PCR-positive sam-
ples. In immunohistochemistry, no individual N. caninum
tachyzoites could be detected in the same respective brain
samples.
Serology
The humoral immune responses of the different animal
groups are shown in Fig. 1. Non-medicated infected calves
developed a relatively high anti-N. caninum antibody
concentration, the corresponding seroconversion started
by the day range 10–20 p.i.. The calf group that had re-
ceived ponazuril treatment for a period of 6 consecutive
Figure 2
Average rectal temperatures followed for the first 12 days p.i. in non-infected negative control calves (c), infected and non-
medicated positive control calves (I_w/oT), infected and one-day medicated calves (I_1T) and infected and six-day medicated
calves (I_6T). The dotted horizontal bar indicates the upper level of the normal body temperature in this age class.
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Concentration of ponazuril in serum from calves either given a 1-day-dose (four calves nos. 1T.1 – 1T.4) or a daily dose for 6
consecutive days at 20 mg/kg body weight (five calves nos. 6T.1 – 1T.5). Lacking lines and markers indicate that no sample was
analyzed for this time point.
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body response and a delay in seroconversion when com-
pared to infected (and non-medicated) controls.
Conversely, the anti-N. caninum antibody concentrations
of infected and one-day-medicated calves were only
slightly below those of non-treated animals, differences
were non-significant .
Clinical and pathophysiological parameters
Rectal temperature
The body temperature of calves was assessed daily for the
first 20 days, subsequently weekly until the end of experi-
ments. Fig. 2 shows the average body temperature for the
different groups of animals for the first 12 days p.i., as in
the subsequent periods no average elevations could be
seen anymore. Due to the relative low number of animals,
a statistical evaluation of the significance of differences
could not be performed. Nevertheless, a clear tendency
was observed in the two ponazuril-treated groups, which
both exhibited lower average body temperatures for the
first 5 days p.i. (average peak maximum 39.8C for treated
and 40.0C for non-treated calves) and also a shorter time
period of elevated ( 39.2C; [14]) body temperature (av-
erage 3–4 days for treated and 6 days for non-treated
calves, respectively).
Gain of body weight
Body weight of each animal was assessed weekly from the
time point of purchase (approximately 4–5 weeks prior to
experiments) until the end of all experiments (euthanasia
of calves). In order to address potential differences be-
tween the different animal groups, the groups were com-
paratively clustered in time periods before experiments
(all calves were then equally hold and nourished = pre-ex-
perimental control phase) and experimental time periods.
All groups showed an average gain in body weight that
was not different from the other groups (Table 2).
Determination of blood metabolites and enzymes
Serum levels of glucose, urea, non-esterified fatty acids
and triglycerids, enzymes [(aspartate-amino-transferase
(AST), gamma-glutamyle-transferase (-GT), creatine-ki-
nase (CK) and glutamate-dehydrogenase (GLDH)] were
assessed in blood samples obtained from all animals on
days 0, 1, 2, 3 and 4 p.i.. Within the first four days p.i., no
differences became apparent between any groups of ani-
mals, respective to infection and medication status.
Ponazuril serum levels
Ponazuril serum levels were determined for a selected
number of animals, according to the list and time sched-
ule shown in Fig. 3. The oral absorption of ponazuril was
rapid, and serum concentrations became apparent at the
second day of treatment (= day 3.p.i.). A marked differ-
ence in the maxima and length of detectable ponazuril
concentrations was seen between the one-day and the six-
day-medication. Serum concentrations in the 1-day-dose
had reached a steady state between days 5 and 7 p.i.. Six-
day medication led to an accumulation of the compound
in the serum, so that the maximal concentration peaks
were reached between days 8 and 12 p.i.. Accumulation
was documented by an approximate 3 to 4-fold increase
of the concentration maxima in 6-day-treated versus 1-
day-treated calves. Following discontinuation of chemo-
therapy, at latest on day 47 p.i. for the 1-day-treatment
and on day 82 for the 6-day-treatment, the serum concen-
trations had dropped below 1 mg/l. From the 8 animals
investigated in this part of the study, the mean half life
time, calculated upon concentrations of the active sub-
stance, was 9.8 days.
Discussion
Neosporosis is a disease affecting predominantly the fetal
development in bovine hosts, it may also cause neu-
romuscular dysfunction in infected new born calves and
pups [2]. In cattle, the outcome of a N. caninum infection
appears largely dependent upon the effectiveness of the
immune system of the mother animal [15]. Thus, in a cer-
tain number of cases, immunity appears insufficient to
prevent vertical transmission to the bovine fetus [15].
Chemotherapeutical treatment of neosporosis may be an
issue, provided that an appropriate drug is made availa-
ble. In this respect, we have previously described the use
Table 2: Gain in body weight (average per group) in relation to the initial weight of each calf at its time point of purchase. Animal groups 
included non-infected (control) and N. caninum-infected calves without and with ponazuril therapy (1T = medication for one day; 6T = 
medication for 6 consecutive days). 1 refers to the gain of body weight in the period between purchase and initiation of experiments 
(day of infection with or without treatment) and 2 to the time period between start and end of experiments.
non-infected controls infection, without therapy infection, with therapy_1T infection, with therapy_6T
1 (%) 1.2 1.3 1.6 1.5
2 (%) 2.2 2.2 2.4 1.9
(%) value 1 refers to the initial body weight assesed at the time point of purchase.Page 7 of 10
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uril and ponazuril for the prevention of parasite dissemi-
nation and subsequent cerebral lesion formation [7]. We
now addressed – in a first step – the question, if the same
drug would exhibit a basic effect in the experimentally in-
fected bovine host. This question was tackled in view to
justify and plan future trials for the treatment of experi-
mentally and naturally acquired bovine neosporosis.
With regard to our experimental design, the high costs of
experimental calves did not allow to directly plan experi-
ments with number of calves allowing statistical analyses.
Thus, the project was basically designed as an explorative
study, only allowing to document descriptively the effect
of the treatment in experimentally infected calves. Con-
versely to our previous study in mice, where we had start-
ed chemotherapy 6 hours prior to infection, we now
provided a 24 hour cycle to the parasite to establish and
multiply within the animals, before medication was start-
ed. Chemotherapy itself was either performed as a short
term, one-day medication or as a 6-consecutive-day med-
ication. Assessment of serum levels of ponazuril showed
that the two medication schedules considerably influ-
enced the maximal serum concentrations in the animals.
The relatively long half-life time of ponazuril led to an ac-
cumulation of the compound in 6-day-treated animals, so
that the maximal peak was approximately 3 to 4-times
higher than in 1-day-medicated calves. Also the duration
of ponazuril detectability in serum was markedly longer
in 6-day-treated animals. Nevertheless, no differences ap-
peared between the two treatment schedules as in none of
the treated animals N. caninum became detectable by
PCR. With regard to the non-medicated control calves,
which had received the same infection dose, we had to no-
tify that only 3 out of 6 animals reached the infection
stage where the parasite became detectable by PCR in the
brain and muscles. Calves therefore seemed to exhibit,
constitutively, a relatively low susceptibility to experimen-
tal infection. Similar observations had already been re-
ported by others [16]. Nevertheless, the absence of any
DNA detectability in treated calves versus the 50% de-
tectability in non-treated calves indicate efficacy of pona-
zuril to suppress parasite dissemination and
establishment in peripheral organs such as brain and
muscles. Histology and immunohistochemistry, probably
because of the low infection intensity, did not result in the
demonstration of parasites and respective lesions in the
PCR positive tissues. Uggla et al. [16] had orally infected
calves with N. caninum-tachyzoites. Similarly to our re-
sults, although their animals seroconverted upon infec-
tion, and some became positive by PCR, neither
pathognomonic tissue damages nor parasites themselves
could be demonstrated by histology and immunohisto-
chemistry.
In our mouse model [7], we had shown that toltrazuril/
ponazuril treatment, in parallel to abrogating parasite dis-
semination, also predominantly influenced the kinetics of
the humoral immune response. Similarly now in calves,
experimentally infected and non-treated animals devel-
oped a marked humoral immune response, seroconver-
sion occurred between days 10 and 20 p.i., and maximal
serum antibody concentrations were reached between
days 30 and 40 p.i.. One-day medication of infected calves
– although abrogating parasite detectability by PCR – did
not change the time point of seroconversion and the anti-
body concentration levels when compared to non-treated
animals. Conversely, the 6-day-treatment markedly re-
duced the concentration maximum of serum antibodies,
and delayed the time point of seroconversion by approxi-
mately one week. These findings indicate that the one-day
treatment may not have killed the parasite as efficiently or
rapidly as the 6-day treatment. A higher antibody concen-
tration may be linked either to a higher antigen concentra-
tion (indicating post-infectional parasite multiplication
despite treatment) or to a longer lasting stimulation with
identical antigen concentrations (indicating a longer sur-
vival of the inoculated parasite population). This question
will require appropriate experiments to be addressed.
When tackling clinical parameters during the first phase of
the experiments, it became apparent that non-treated as
well as treated calves responded with fever to the infec-
tion. However, treated animals had milder fever as ex-
pressed by average lower peak levels and shorter fever
periods. As the first fever occurred only 1–2 days after ex-
perimental infection in non-treated and 2–3 days p.i. in
treated animals, we can exclude endotoxin activity by in-
oculated N. caninum tachyzoites. Principally, endotoxin
induced fever is expected to occur a few hours after inocu-
lation of e.g. lipopolysaccharides (LPS) [14]. Inoculation
of an appropriate number of Vero-cells in non-infected
control animals did not result in fever, indicating that fe-
ver was indeed related to the parasite inoculum. In conse-
quence, we can conclude that ponazuril therapy inhibited
the parasite proliferation in a way to reduce fever. To elu-
cidate the fever aspect more in details, we will have to per-
form experimental inoculation of the same dose but of
killed parasites (such as done in the previous mouse ex-
periments; [7]). With these experiments we will be able to
show if fever is directly associated to viable trophozoites
or not.
Bovine N. caninum infection, although not demonstrating
any acute-phase symptoms, may result in chronic phase
consequences, as indicated by reduced gain of body
weight in seropositive versus seronegative calves [18]. In
our experiments, however, no respective differences be-
came apparent. While planning the experiments, we hy-
pothesized that a putative intensive parasitePage 8 of 10
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and organ damages, respectively, and thus also in the
modification of blood parameters. Therefore, we analyzed
serum glucose, GLDH and -GT to address liver functions,
AST and CK for muscle damages, urea for kidney damages
and triglycerides and NEFA to check the lipid status. All re-
sults were within the normal range of concentrations [19–
21], thus indicating the absence of any pathology that
could have been demonstrated with the respective labora-
tory tools [22]. These findings support again our hypoth-
esis on the relatively low susceptibility of calves for
experimental N. caninum infection. Therefore, even if the
parasite became disseminated and subsequently estab-
lished in the brain and muscles of at least 3 from 6 infect-
ed and non-treated calves, the clinical consequences of
this infection became not detectable.
Conclusions
Based upon our findings in this initially explorative ap-
proach that indicate a basic effectiveness of ponazuril
against experimental N. caninum infection in calves, we
plan to follow our chemotherapeutical intervention strat-
egy to control bovine neosporosis with a subsequent
more extensive field study. This will now tackle naturally
infected calves derived from N. caninum-positive mothers.
This field study will be designed in view to include a large
number of animals of appropriate statistical significance.
Parameters to asses efficacy of treatment will include the
same as used in this study. Conceptually, there is a general
acceptance that healthy newborn calves from N. caninum-
positive mothers are suspected to stay life-long chronical-
ly infected [23], with reactivations occurring during preg-
nancy. Elimination of the parasite after birth by
chemotherapy may provide negative off-spring and thus
N. caninum-free breeding lines. Furthermore, as the milk
yield and gain of body weight appeared to be reduced in
persistently infected cows [18], creation of Neospora-free
breeding lines may also improve other economic aspects.
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